Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0002007919-25-000015·Inhibrx Biosciences, Inc.
Schedule 13D ownership disclosure
Inhibrx Biosciences Inc
Common Stock, par value $0.0001 per share · CUSIP: 45720N103
Event date: 2024-06-03
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- The Jon F. Kayyem and Paige Gates-Kayyem Family TrustReported CIK 0001821293
Shares: 509,360.00 · Class: 3.5%
- Jon Faiz KayyemReported CIK 0001366268
Shares: 1,149,046.00 · Class: 7.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002007919-25-000015
- Form type
- SCHEDULE 13D/A
- Filer
- Inhibrx Biosciences, Inc.
- CIK
- CIK 2007919
- Filed
- Feb 26, 2025
- Reporting period
- Jun 03, 2024
- Description
- Schedule 13D beneficial ownership